MAR-ATENOLOL 25 MG
ATENOLOL : 25 MG · DIN 02371979 · MARCAN PHARMACEUTICALS INC
Health Canada status: MARKETED
What is MAR-ATENOLOL?
MAR-ATENOLOL 25 MG contains ATENOLOL : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02371979, held by MARCAN PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 22-Oct-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MAR-ATENOLOL used for?
MAR-ATENOLOL (atenolol tablets) is indicated in: patients with mild or moderate hypertension. It is usually used in combination with other drugs, particularly a thiazide diuretic. However, it may be tried alone as an initial agent in those patients in whom, in the judgement of the physician, treatment should be started with a beta - blocker rather than a diuretic. Atenolol may be used in combination with diuretics and/or vasodilators to treat severe hypertension. The combination of atenolol with a diuretic or peripheral vasodilator has been found to be compatible. Limited experience with other antihypertensive agents has not shown evidence of incompatibility with atenolol. Atenolol is not recommended for the emergency treatment of hypertensive crises. the long - term management of patients with angina pectoris due to ischemic heart disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02371979 |
|---|---|
| Brand name | MAR-ATENOLOL |
| Generic / active ingredient | ATENOLOL : 25 MG |
| Manufacturer | MARCAN PHARMACEUTICALS INC |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C07AB03 ATENOLOL |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Oct-2012 |
How is it stored and handled?
null
How is it supplied?
HDPE bottles of 100 and 500
Is ATENOLOL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C07AB03 ATENOLOL. 28 of 87 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-ATENOL TAB 100MG | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 00773697 |
| APO-ATENOL TAB 50MG | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 00773689 |
| ATENOLOL | 100 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00828793 |
| ATENOLOL | 100 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02238318 |
| ATENOLOL | 25 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02326701 |
| ATENOLOL | 25 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02541564 |
| ATENOLOL | 50 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00828807 |
| ATENOLOL | 50 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02238316 |
| JAMP-ATENOLOL | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02367572 |
| JAMP-ATENOLOL | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02367556 |
Who else supplies ATENOLOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ATENOLOL appears in 359 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.